← Back to Search

EIM Testing for Neuromuscular Disorders

N/A
Recruiting
Led By Tanya J Lehky, M.D.
Research Sponsored by National Institute of Neurological Disorders and Stroke (NINDS)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of study
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new, noninvasive, and painless electrical muscle testing device to see if it is helpful in evaluating muscle disorders and nerve disorders. Healthy volunteers and those with neuromuscular diseases are eligible.

Who is the study for?
This trial is for healthy individuals and those with neuromuscular diseases, aged 2 years or older. Participants must be in good health as determined by medical history, willing to follow study procedures, and able to give informed consent. Children (7-18) and adults (18+) can join; however, NIH employees involved in EMG studies cannot participate.
What is being tested?
The trial tests Electrical Impedance Myography (EIM), a technique that measures how electrical currents travel through muscles. It's compared with other standard tests like muscle ultrasonography, nerve conduction studies, and Electromyography (EMG). The goal is to evaluate its effectiveness in diagnosing various neuromuscular disorders.
What are the potential side effects?
There are minimal side effects expected from EIM testing since it's noninvasive. However, participants may feel a small shock during nerve conduction studies or discomfort when a thin needle is inserted into the muscle for EMG.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of study
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Healthy Volunteers - EIM measures for a selection of muscles with the aim of developing normative values for the NIH EMG lab
Patients - EIM measures for a selection of muscles
Secondary study objectives
Healthy Volunteers - exploratory correlations of ultrasound and electrodiagnostic methods such nerve conduction studies and less likely, EMG
Serial studies in pediatric patients

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1/All SubjectsExperimental Treatment4 Interventions
Healthy Volunteers and patients
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Electromyography (EMG)
2019
N/A
~260

Find a Location

Who is running the clinical trial?

National Institute of Neurological Disorders and Stroke (NINDS)Lead Sponsor
1,385 Previous Clinical Trials
652,413 Total Patients Enrolled
46 Trials studying Motor Neuron Disease
21,242 Patients Enrolled for Motor Neuron Disease
Tanya J Lehky, M.D.Principal InvestigatorNational Institute of Neurological Disorders and Stroke (NINDS)
3 Previous Clinical Trials
591 Total Patients Enrolled

Media Library

Electrical Impedance Myography Clinical Trial Eligibility Overview. Trial Name: NCT01900132 — N/A
Motor Neuron Disease Research Study Groups: 1/All Subjects
Motor Neuron Disease Clinical Trial 2023: Electrical Impedance Myography Highlights & Side Effects. Trial Name: NCT01900132 — N/A
Electrical Impedance Myography 2023 Treatment Timeline for Medical Study. Trial Name: NCT01900132 — N/A
~10 spots leftby Jun 2025